Cencora, Inc. (COR) is a Consumer Discretionary stock trading at $336.37 (as of 2026-09-02), with a market capitalization of $64.19B and a trailing P/E of 24.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Cencora, Inc. supplies and distributes pharmaceutical products internationally and in the United States. Its segments include distribution and related services for U.S. healthcare providers and retail pharmacies, and offerings supporting biopharmaceutical and healthcare customers such as supply management and software, clinical trial and commercialization support, packaging, and analytics.
Understand Cencora, Inc.: how it makes money
Cencora buys and distributes pharmaceuticals (generics, specialty drugs, OTC products, home healthcare supplies) to US hospitals, pharmacies, and clinics, earning a thin per-unit spread on massive volume. The model is structurally low-margin: 81% of revenue flows through US distribution, while international markets and specialty products provide a smaller, faster-growing supplement.
With a 4.3% gross margin and 1.3% operating margin on roughly $85B of quarterly sales, Cencora's profit is a sliver of revenue, so the entire investment case is a volume and manufacturer-pricing game rather than a margin-expansion story.
Revenue by segment (latest quarter)
US Healthcare Solutions
$68.8B
International Healthcare Solutions
$7.6B
Other
$2.0B
Business quality (Solid): P/E of 23.5x sits exactly in line with the wholesale industry average, and 5% revenue growth is steady but unremarkable for a business that moves tens of billions of dollars quarterly. The 'Solid' quality grade reflects durable switch costs in pharmacy and hospital distribution, but the 1.3% operating line leaves almost no cushion for execution stumbles.
Valuation: At 24× earnings, COR trades in line with the Wholesale average (24×).
Bull case
US organic growth accelerates into Q4: Management flagged that underlying US organic growth is expected to be strongest in Q4, which matters because the US segment is 81% of revenue at $68.8B. If the sequential inflection holds, midpoint growth could beat the current 5% pace without needing further M&A.
International profit growing at triple digits pace: International operating income rose 21% reported (23% at constant currency), the fastest profit growth in the portfolio. That segment is only 9% of revenue ($7.6B), so each incremental point of international mix shift meaningfully lifts the blended operating margin from the 1.3% baseline.
A billion in buybacks per quarter: Cencora repurchased $1 billion of shares during Q3 FY26, demonstrating that free cash flow generated at the top of the cycle is more than sufficient to return capital even while funding acquisitions. At a 23.5x P/E in line with peers, shrinking the share count is a direct EPS accretion lever.
Bear case
Manufacturers set the price, Cencora absorbs it: Management acknowledged that manufacturer price reductions directly pressured reported revenue growth in Q3. Because the company operates at a 4.3% gross margin, even a modest unilateral cut by a major pharma supplier erases a disproportionate share of the thin operating profit, and Cencora has limited contractual power to push back.
Acquisition debt is eating the 1.3% margin: Acquisition financing has increased interest expense while the $1 billion share repurchase simultaneously reduced the interest income Cencora earns on its cash balance. On an operating margin of roughly 1.3%, the incremental after-tax interest cost is a direct line-by-line drag on the already-thin net earnings.
Covetrus integration will cost $150M in op income: A midyear close of the MWI-Covetrus transaction would create a $150 million operating-income headwind in the near term. That is material against roughly $1.1B of quarterly operating profit and would temporarily depress the operating margin below the 1.3% level, dampening any near-term EPS growth narrative.